Last reviewed · How we verify
DM-1992
DM-1992 is a small molecule that targets the central nervous system to treat pain.
DM-1992 is a small molecule that targets the central nervous system to treat pain. Used for Chronic pain.
At a glance
| Generic name | DM-1992 |
|---|---|
| Sponsor | Depomed |
| Drug class | opioid |
| Target | opioid receptor |
| Modality | Small molecule |
| Therapeutic area | Pain |
| Phase | Phase 2 |
Mechanism of action
DM-1992 works by modulating the activity of certain ion channels in the brain, which helps to reduce the transmission of pain signals. This mechanism is thought to be responsible for its analgesic effects.
Approved indications
- Chronic pain
Common side effects
- Nausea
- Dizziness
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DM-1992 CI brief — competitive landscape report
- DM-1992 updates RSS · CI watch RSS
- Depomed portfolio CI